dendritic cells transfected with hTERT, survivin, and tumor cell derived mRNA

An investigational **autologous dendritic-cell cancer vaccine** prepared by loading dendritic cells with messenger RNA encoding human telomerase reverse transcriptase and survivin, together with tumor-cell-derived mRNA. The transfected dendritic cells are intended to present these tumor-associated antigens and stimulate antigen-specific antitumor T-cell responses against melanoma cells expressing hTERT, survivin, and patient-derived tumor antigens. It was evaluated in an investigator-sponsored Phase I/II study in metastatic malignant melanoma; the registered study was terminated. The broader protocol also used temozolomide before vaccination and offered lymphodepletion followed by ex vivo-expanded autologous T-cell reinfusion to patients demonstrating an immune response. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT00961844/))

Other names

dendritic cells transfected with hTERT, survivin, and tumor cell derived mRNAdendritic cells transfected with hTERT, survivin, and tumor cell-derived mRNA